Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy

Yanagihara, Shigeto; Sugita, Kazunari; Yoshida, Yuichi; Tsuruta, Daisuke; Yamamoto, Osamu

doi:10.1684/ejd.2016.2939

Cited by 20 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the recombination among HBV virus genotypes is well known and not infrequent [23], and is not linked to treatment with biologic drugs. To our knowledge, only five patients with HBV infection have been treated so far with secukinumab and, similarly to our case, HBV reactivation or elevation in liver enzymes was not found [24,25]. In this regard, several studies have shown that Th17 cells play a critical role in the pathogenesis of viral hepatitis, with serum levels of IL-17 being able to predict the severity of liver damage and fibrosis [26].…”

Section: Discussionsupporting

confidence: 73%

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Galluzzo

Talamonti

Simone

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 73%

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Galluzzo

Talamonti

Simone

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…He received secukinumab 300 mg at 0, 1, 2, 3, 4, 8, 12, 16, and 20 weeks. His PASI score improved and returned to almost 0 after treatment [52].…”

Section: Hbv and Hcvmentioning

confidence: 92%

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

Merola

Feldman

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Psoriasis (PsO) is a common, systemic, chronic, inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling. PsO is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies. Furthermore, special populations, such as pregnant, pediatric, and elderly patients, and those with erythrodermic PsO, are challenging to treat and require tightly monitored disease and treatment management. Because certain populations have demographic or clinical characteristics that can affect the presentation of PsO and complicate treatment responses, these patient populations are largely excluded from clinical trials; therefore, most clinical evidence for the treatment of these patients is derived from case reports and series. Secukinumab, a fully human monoclonal interleukin-17A antibody, has been shown in several clinical trials to be effective and safe for the treatment of PsO; however, these studies offer only limited data on the use of secukinumab in patients with chronic illnesses or in special populations. This review explores the use of secukinumab for PsO in special populations, including pregnant women, children, elderly people, patients with erythrodermic PsO, and those with chronic illnesses, including latent tuberculosis, hepatitis B and C, HIV, multiple sclerosis, and malignancies.

show abstract

“…There are a few reports describing the treatment of psoriasis patients who are HBV carriers with IL-17 inhibitors; anti–IL-17A antibody monotherapy 1 or anti–IL-17A antibody and nucleoside analogs combination therapy 2 . Consultation with a hepatologist is strongly recommended when treating psoriasis patients with biologic therapy who have HBV 3 .…”

Section: Discussionmentioning

confidence: 99%

An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis

et al. 2019

View full text Add to dashboard Cite

Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy

Cited by 20 publications

References 9 publications

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence

An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis

Contact Info

Product

Resources

About